According to the Financial Times, vaccine developers Pfizer and Moderna have raised the price of the new crown vaccine in the EU market. The newspaper reported that Pfizer's price has risen from €15.50 to €19.50 and has seen some new contracts with the EU.
According to the contract, the cost of the Moderna vaccine was 19 euros per dose, and now it is 21.50 euros.
According to EU contract sources, this is less than the previously agreed 24 euros because more vaccines were ordered.
Europe is willing to pay higher prices to ensure supply obtained from European factories.
Earlier this year, the two parties agreed to supply about 2 billion doses by 2023. Now it seems that the two messenger ribonucleic acid (mRNA) vaccines are better than AstraZeneca and Janssen vaccines, although the latter is cheaper.
According to sources, pharmaceutical companies have "evaluated their market value" and are using the usual business practice: the vaccine is effective and the value has increased.
rich countries pay the highest fees
Pfizer CEO Albert Bourla said that middle-income countries pay about half of the price that rich countries, while low-paying countries only pay the cost price.
The contract with the EU was signed when problems arise between AstraZeneca and Johnson & Johnson were first suspected of a link between these vaccinations and rare blood clots.
Pfizer and Moderna Pharmaceuticals are expected to generate tens of billions of dollars in revenue this year as more contracts are signed with countries that want to ensure there is enough stock for an additional round of vaccination. This may be necessary due to the emergence of the highly contagious Delta variant of the coronavirus.
Pfizer increased its revenue forecast by nearly a third to €28.2 billion last week after sales doubled in the second quarter.
